Ultragenyx Pharmaceutical (RARE) Operating Income (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Operating Income of -$169.0 million for Q1 2026, down 18.18% year-over-year from -$206.6 million in Q1 2025, and down 49.18% quarter-over-quarter from -$113.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Operating Income (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Operating Income for 14 consecutive years, with -$169.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 18.18% year-over-year to -$169.0 million; the TTM figure through Mar 2026 stood at -$561.1 million (down 9.23% YoY), while the FY2025 annual figure was -$535.0 million, changed 0.19% from the prior year.
- Operating Income slipped to -$169.0 million in Q1 2026 per RARE's latest filing, from -$113.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$107.9 million in Q2 2025 and bottomed at -$225.1 million in Q3 2022.
- Historically, Operating Income has averaged -$144.6 million across 5 years, with a median of -$143.0 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Income sank 150.55% — and 2023, when it soared 35.53%.
- Ultragenyx Pharmaceutical's Operating Income stood at -$145.6 million in 2022, then climbed by 16.33% to -$121.8 million in 2023, then dropped by 0.38% to -$122.3 million in 2024, then climbed by 7.38% to -$113.3 million in 2025, then tumbled by 49.18% to -$169.0 million in 2026.
- Business Quant data shows RARE's Operating Income at -$169.0 million in Q1 2026, -$113.3 million in Q4 2025, and -$170.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -75.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.00 Mn |
| Mar 31, 2026 | -169.00 Mn |
| Dec 31, 2025 | -113.28 Mn |
| Sep 30, 2025 | -170.89 Mn |
| Jun 30, 2025 | -107.89 Mn |
| Mar 31, 2025 | -143.00 Mn |
| Dec 31, 2024 | -122.31 Mn |
| Sep 30, 2024 | -131.99 Mn |
| Jun 30, 2024 | -116.36 Mn |
| Mar 31, 2024 | -165.35 Mn |
| Dec 31, 2023 | -121.84 Mn |
| Sep 30, 2023 | -145.10 Mn |
| Jun 30, 2023 | -147.96 Mn |
| Mar 31, 2023 | -154.11 Mn |
| Dec 31, 2022 | -145.63 Mn |
| Sep 30, 2022 | -225.07 Mn |
| Jun 30, 2022 | -141.59 Mn |
| Mar 31, 2022 | -136.63 Mn |
| Dec 31, 2021 | -102.56 Mn |
| Sep 30, 2021 | -89.83 Mn |